F.D.A. Faces Upset Over Denials of New Drugs
Agency officials promise fast reviews of new treatments while vowing they will not be a “rubber stamp” for the industry. But patients with rare diseases view recent decisions as signs that the doors are closing on their options.
📰 Original Source
Read full article at Nytimes →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.